Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Regentis Biomaterials logo — Pioneering innovative hydrogel solutions for tissue regenera...

Regentis Biomaterials

Pioneering innovative hydrogel solutions for tissue regeneration through advanced scientific development

Founded 2004 Grant Total: $35.62M Biotechnology, Health Care +1

General Information

Company Name Regentis Biomaterials
Founded Year 2004
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Regentis Biomaterials. To contact Regentis Biomaterials, visit regentis.co.il.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Regentis Biomaterials

Regentis Biomaterials is a pioneering company dedicated to the development and commercialization of unique hydrogels for tissue regeneration. With their primary technology being the biodegradable hydrogel known as Gelrin™, crafted from polyethylene glycol diacrylate and denatured fibrinogen, the company integrates the durability of synthetic materials with the biological functionality of natural substances. Dr. Dror Seliktar originally created the Gelrin hydrogel platform at Technion University. Regentis Biomaterials' leading product, GelrinC™, is currently undergoing clinical trials for treating articular cartilage lesions after extensive preclinical and safety evaluations. Founded in 2004, the company operates in the Biotechnology, Health Care, and Medical Devices industries. Their most recent investment of €3.12M came in the form of a grant from EASME - EU Executive Agency for SMEs on 01 January 2019.

Taxonomy: biomaterials, hydrogels, tissue regeneration, polyethylene glycol diacrylate, fibrinogen, Regentis Biomaterials, Gelrin, Technion University, clinical trials, articular cartilage, preclinical testing, biodegradable materials

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €3.12M 1
EASME - EU Executive Agency for SMEs
01 Jan 2019
Series D $15.00M 5
Medica Venture Partners SCP Vitalife Partners
Medica Venture Partners, SCP Vitalife Partners +3
07 Feb 2016
Series C $10.00M 3
DSM Venturing Medica Venture Partners SCP Vitalife Partners
DSM Venturing, Medica Venture Partners +1
14 May 2012
Series B $7.50M 1
ProSeed Venture Capital Fund
ProSeed Venture Capital Fund
21 Aug 2007
Seed Round Undisclosed -
01 Sep 2004

Regentis Biomaterials Alternatives & Competitors

View All Alternatives
Regentis Biomaterials vs
4D Biomaterials
4D Biomaterials United Kingdom

4Degra® 3D printing biomaterials - helping people heal. Regenerative, resorbable and customisable.

Seed
9 employees
Biotechnology, Health Care
Regentis Biomaterials vs
LATTICE MEDICAL
LATTICE MEDICAL France

Specialising in tissue engineering and 3D printing, we develop innovative implants for soft tissue r...

Non Equity Assistance
24 employees
Biotechnology, Health Care
Regentis Biomaterials vs
ORTEQ Sports Medicine
ORTEQ Sports Medicine United Kingdom

We aim to reduce patient suffering from meniscus and articular cartilage injury or degeneration by c...

Venture round
9 employees
Biotechnology, Health Care
View all alternatives

FAQ About Regentis Biomaterials

Pioneering innovative hydrogel solutions for tissue regeneration through advanced scientific development
Regentis Biomaterials was founded in 2004.
Regentis Biomaterials operates in Biotechnology, Health Care and Medical Devices. Its work centres on biomaterials, hydrogels, tissue regeneration and polyethylene glycol diacrylate.
Regentis Biomaterials has completed 5 funding rounds, raising a total of $35.62M. The latest funding stage is Grant.
Top alternatives and competitors to Regentis Biomaterials include 4D Biomaterials, LATTICE MEDICAL, ORTEQ Sports Medicine. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Regentis Biomaterials and 4D Biomaterials are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Regentis Biomaterials, https://bouncewatch.com/company/regentis-biomaterials, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes